Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAD, Academy, accuracy, Acorda, Affentranger, Afsaneh, Alavi, albumin, alfa, ALX, anaphylatoxin, antigen, apremilast, ascending, asunercept, atezulizumab, Bain, baricitinib, beleggen, beta, BTK, Burton, buyer, carbon, CDO, cemiplimab, cephalosporin, chemical, chemotherapeutic, Chinese, cleantech, climate, clindamycin, concomitantly, cosibelimab, COSO, Cox, CPAP, cream, CSO, customarily, CXC, cybersecurity, cyclic, cytochrome, cytotoxic, dapsone, dataset, delivery, Dentistry, depemokimab, depiction, depressed, descedent, deteriorate, dialogue, disqualification, disruptor, Division, downturn, doxorubicin, drempel, dynamic, editing, effectual, ELR, en, EP, etrasimod, expressly, extracellular, extraordinary, extrapolated, fuel, furlough, fusion, gas, gave, gemcitabine, gene, genital, geopolitical, Gohibic, graph, greenhouse, grondslag, hamster, harmour, hazard, heart, heffingvrij, hemoglobinuria, HHS, hydrolase, ICT, imiquimod, immunoglobulin, imsidolimab, inkomen, insertion, Instruction, intralesionally, intramuscular, Intratumorally, invasively, ipilimumab, izokibeb, JAK, junior, Lastly, Leqembi, leukotriene, locoregional, logistic, logistical, LTI, MAP, Maraba, Mayo, meantime, media, Mei, MEK, melanoma, metabolism, metronidazole, micro, microtubule, military, monovalent, moratlity, mucin, myeloid, nangibotide, nanobody, nanrilkefusp, necessitating, neurological, neutropenia, nihil, NMPA, Noncurrent, nondepleting, nuclear, oil, oncolytic, orimsilast, orismilast, ORR, PANAMO, peildatum, Pemphigoid, people, peptide, peptidic, persistent, Peter, photoimmune, plasmin, Po, postpone, povorcitinib, printed, pustular, radical, radiological, regression, remibrutinib, rendement, rendementspercentage, reproduce, resistant, resorcinol, rifampicin, RIST, Road, robust, route, routine, ruxolitinib, sabizabulin, Samsung, sefe, sentiment, serum, session, shutdown, sixty, sonelokimab, spanning, sparen, spesolimab, Spinraza, stagnation, stipulated, stratification, subpopulation, subunit, sudden, summer, superagonist, superficial, synthetic, Tai, tapered, taxane, Tecfidera, tetracycline, thrombin, timeframe, timeline, tirbanibulin, tocilizumab, tolearated, tow, transgenic, trap, trivalent, tyrosine, unapproved, unexercised, unlocked, unqualified, unresectable, untreated, vector, vegetative, Veru, Vilwaysi, voordeel, wage, Ward, Western, wouldthen, zilicoplan, zunsemetinib
Removed:
abbvie, absolute, absorb, Affentrager, aggregation, al, Ammann, ANCOVA, Anstalt, arithmetic, Asia, asserted, attached, attest, avoided, Bausch, biopharma, Biovitrum, brand, characterize, chemocentryx, Chugai, CIMA, Cloud, conference, confirmation, congregating, convince, costimulation, degranulation, detrimental, DF, diagnosed, discretionary, DLQI, drop, easier, economy, elaborated, eleven, emergent, epyx, escalating, escalation, exacerbation, execution, expedited, explained, extendable, ffentlichen, fistula, Floor, Florida, France, functionality, Gall, Genentech, genitalia, globally, golden, graft, greatest, ground, grouped, handled, Hao, hindered, historic, host, Humira, Hurley, impacting, impairing, imputation, Incyte, insentia, internet, Investco, IXCHANGE, IXPLORE, Janssen, Japanese, Katrin, KfW, Kung, lab, LANexpert, Lina, LP, Ma, machinery, mandated, manuscript, medium, MINE, minimal, missing, MoA, modelling, moving, multicenter, nancial, nodule, nonbinding, numerical, NY, observational, offered, Ohio, OLE, oncology, Ortho, outbreak, parachute, path, percent, petition, Pharma, pharmacodynamic, poster, precautionary, preceded, prioritization, promoter, QUALITATIVE, QUANTITATIVE, quicker, ra, reform, remediation, Remicade, remote, remotely, rendementgrondslag, RESERVED, revealed, revision, rheumatoid, Ritximab, rose, Russia, Salix, SB, Schweiz, SILIQ, Sloan, solve, Squibb, stable, strongest, subset, surprisingly, suspending, Swedish, switching, tailored, TEAE, Technologie, terrorism, thousand, transitioning, translate, twelve, unblinding, unwilling, Uschmann, visit, Wang, war, weaken, weakened, weakening, weekly, Wilcoxon, window, Yautong, York, Zurich
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 1.1 Articles of Association of Inflarx N.V., Dated August 25, 2021
- 2.4 Description of Rights of Each Applicable Class of Securities Registered Under Section 12 of the Securities Exchange Act of 1934.
- 4.4 Addendum No. 2, Dated As of November 9, 2022, Between Inflarx GMBH and Beijing Defengrei Biotechnology Co. LTD.
- 8.1 List of Subsidiaries
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Consent of Ernst & Young GMBH Wirtschaftsprufungsgesellschaft
- Download Excel data file
- View Excel data file
IFRX similar filings
Filing view
External links
Exhibit 13.1
CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of InflaRx N.V. (the “Company”) for the fiscal year ended December 31, 2022 (the “Report”), I, Niels Riedemann, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
1. | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 22, 2023
/s/ Niels Riedemann | |
Chief Executive Officer | |
(Principal Executive Officer) |